Literature DB >> 21544728

Anticancer potential of magnolol for lung cancer treatment.

Jae-Uk Seo1, Min-Ho Kim, Hyung-Min Kim, Hyun-Ja Jeong.   

Abstract

Lung malignancy is a major cause of human mortality. As such, safe pharmacological agents that can detect lung cancer are urgently required. Magnolol has been reported to have anticancer property. However, it is still unclear whether magnolol induces apoptosis of lung carcinoma cells. In this study, magnolol inhibited cell growth, increased lactate dehydrogenase release, and modulated cell cycle in human lung carcinoma A549 cells. Magnolol induced the activation of caspase-3 and cleavage of Poly-(ADP)-ribose polymerase, and decreased the expression level of nuclear factor-κB/Rel A in the nucleus. In addition, magnolol inhibited basic fibroblast growth factor-induced proliferation and capillary tube formation of human umbilical vein endothelial cells. These data indicate that magnolol is a potential candidate for treating of human lung carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544728     DOI: 10.1007/s12272-011-0413-8

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  10 in total

1.  Concentration-dependent differential effects of udenafil on viability, proliferation, and apoptosis in vascular endothelial and smooth muscle cells.

Authors:  Cheng-Hu Fang; Yi-Sun Song; Byung-Im So; Hyuck Kim; Jeong-Hun Shin; Kyung-Soo Kim
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

2.  2-O-Methylmagnolol upregulates the long non-coding RNA, GAS5, and enhances apoptosis in skin cancer cells.

Authors:  Tong-Hong Wang; Chieh-Wen Chan; Jia-You Fang; Ya-Min Shih; Yi-Wen Liu; Tzu-Chien V Wang; Chi-Yuan Chen
Journal:  Cell Death Dis       Date:  2017-03-02       Impact factor: 8.469

3.  The protective effects of magnolol on acute trinitrobenzene sulfonic acid‑induced colitis in rats.

Authors:  Yong Zhang; Li-Tang Fu; Fang Tang
Journal:  Mol Med Rep       Date:  2017-12-20       Impact factor: 2.952

Review 4.  Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update.

Authors:  Yiping Lin; Yuke Li; Yuanlian Zeng; Bin Tian; Xiaolan Qu; Qianghua Yuan; Ying Song
Journal:  Front Pharmacol       Date:  2021-03-17       Impact factor: 5.810

Review 5.  Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight.

Authors:  Xiaofeng Wang; Qingqing Liu; Yuanfeng Fu; Ren-Bo Ding; Xingzhu Qi; Xuejun Zhou; Zhihua Sun; Jiaolin Bao
Journal:  Molecules       Date:  2022-09-29       Impact factor: 4.927

6.  Cardiovascular protection of magnolol: cell-type specificity and dose-related effects.

Authors:  Jennifer Hui-Chun Ho; Chuang-Ye Hong
Journal:  J Biomed Sci       Date:  2012-07-31       Impact factor: 8.410

7.  The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy.

Authors:  Ying Liu; Wei Cao; Bo Zhang; Yong-qiang Liu; Zhong-yuan Wang; Yan-ping Wu; Xian-Jun Yu; Xu-dong Zhang; Ping-hong Ming; Guang-biao Zhou; Laiqiang Huang
Journal:  Sci Rep       Date:  2013-11-14       Impact factor: 4.379

8.  Human non‑small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy.

Authors:  Yi-Han Chiu; Shih-Hsien Hsu; Hsiao-Wei Hsu; Kuo-Chin Huang; Wangta Liu; Chang-Yi Wu; Wei-Pang Huang; Jeff Yi-Fu Chen; Bing-Hung Chen; Chien-Chih Chiu
Journal:  Int J Oncol       Date:  2018-08-14       Impact factor: 5.650

Review 9.  Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer.

Authors:  Abhishek Manoj Ranaware; Kishore Banik; Vishwas Deshpande; Ganesan Padmavathi; Nand Kishor Roy; Gautam Sethi; Lu Fan; Alan Prem Kumar; Ajaikumar B Kunnumakkara
Journal:  Int J Mol Sci       Date:  2018-08-10       Impact factor: 5.923

10.  Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation.

Authors:  Chanju Lee; Hyunju Jeong; Hyunji Lee; Minwoo Hong; Seon-Young Park; Hyunsu Bae
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.